Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biocorrx Inc (OP: BICX )

1.548 -0.512 (-24.88%)
Streaming Delayed Price Updated: 10:44 AM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,774
Open 1.770
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 2.060
Today's Range 1.548 - 1.770
52wk Range 0.6502 - 3.540
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety

Performance

YTD
+40.68%
+40.68%
1 Month
-24.88%
-24.88%
3 Month
+82.06%
+82.06%
6 Month
-30.29%
-30.29%
1 Year
-51.64%
-51.64%

More News

Read More
BioCorRx to Present at Sequire Biotechnology Conference on February 2nd
Via NewMediaWire
BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors
Via NewMediaWire
BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Via NewMediaWire
Clear Channel Outdoor, Archer Aviation And These 2 Stocks Under $3 Insiders Are Aggressively Buying
Via Benzinga
BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States
Via NewMediaWire
BioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc.
Via NewMediaWire
BioCorRx Provides Business Update for the Third Quarter of 2022
Via NewMediaWire
BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Via NewMediaWire
BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Via NewMediaWire
Exposures Product Safety
BioCorRx Provides Business Update for the Second Quarter of 2022
Via NewMediaWire
Exposures Product Safety
Meet BioCorRx: The Biotechnology Firm Taking A Specialized Approach To Treating Addictive Disorders
Via Benzinga
BioCorRx to Participate in the Benzinga All Access Event on July 15th
Via NewMediaWire
BioCorRX Inc. Discusses BICX104 Human Trials and 2B3D Metaverse Partnership with The Stock Day Podcast
Via Newsfile
Exposures Product Safety
BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Via NewMediaWire
Topics Death
Exposures Death
BioCorRx Featured on LiveNOW from FOX
Via NewMediaWire
Exposures Product Safety
BioCorRx to Present at the LD Micro Invitational XII on June 7th
Via NewMediaWire
BioCorRx and 2B3D to Pilot First-of-its-Kind PTSD and Addiction Treatment Solutions for Veterans in Metaverse Setting
Via NewMediaWire
BioCorRx Business Update for the First Quarter of 2022
Via NewMediaWire
Keynotes, Educational Panels and 88 Companies to Present at the Planet MicroCap Showcase on May 3-5, 2022 at Bally's Hotel & Casino in Las Vegas, NV
From Stock News Now
Via AccessWire
BioCorRx Begins Recruitment for Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Via NewMediaWire
Exposures Product Safety
BioCorRx to Present at the Planet MicroCap Showcase 2022 in Las Vegas on May 4th
From BioCorRx Inc.
Via AccessWire
BioCorRX Inc. Discusses FDA Approval Process for Implantable Naltrexone Pellet, BICX104, with The Stock Day Podcast
Via Newsfile
Exposures Product Safety
BioCorRx Announces Additional Award of Nearly $100,000 from NIDA for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Via NewMediaWire
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.